Thrombopoietin Receptor Agonist Patient experience survey

Gepubliceerd: 17-06-2021 Laatst bijgewerkt: 18-08-2022

Participant demographics affect the health state. TPO-RA treatment affects the severity of symptoms, overall health condition, health state, overall satisfaction with therapy and reasons for discontinuation. TPO-RA treatment affects direct...

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON22426

Bron
NTR

Verkorte titel
TRAPeze

Aandoening

Immune Thrombocytopenia

Ondersteuning

Primaire sponsor: Sobi
Overige ondersteuning: Sobi

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The relative preferences towards TPO-RA product characteristics

Toelichting onderzoek

Achtergrond van het onderzoek

Real world evidence Burden of Illness cross-sectional study (discrete choice experiment and exploratory questions) to define patient preference towards existing TPO-RAs, to describe disease characteristics, patterns of treatment and satisfaction with therapy and to describe patient demographics, resource use, work and productivity and social impact.
Men or women ≥18 years of age; Formal diagnosis of primary ITP according to the ASH and ICR guidelines; Currently or have previously received a TPO-RA (either eltrombopag and/or romiplostim) in the last 12 months; Have been treated with a TPO-RA for a minimum of 3 months, with at least some of the treatment received in the last 12 months; Provide written informed consent; Ability to understand and respond in English; this does not need to be the participants' first language or even their own language if they wish to use their own translator. If recruitment appears to be limited by this, then translations of the survey will be made. Further plans for deployment will also see the survey translated into French, German, Italian and Spanish

Doel van het onderzoek

Participant demographics affect the health state.
TPO-RA treatment affects the severity of symptoms, overall health condition, health state, overall satisfaction with therapy and reasons for discontinuation.
TPO-RA treatment affects direct healthcare resource utilisation and costs.
TPO-RA treatment affects wider healthcare resource use and costs.

Onderzoeksopzet

Primary endpoint (Participant preferences (or 'choice') towards TPO-RA product characteristics): discrete choice experiment through web platform, starting 1 August 2021 (pending ERC approval) and ending 31 December 2021. Participants have 1 week to fill out the online survey and are expected to need a total of 20 minutes for this.

Secondary endpoints (Participant demographics and disease characteristics, Patterns of treatment and overall satisfaction with therapy, Direct healthcare resource utilisation and costs & Wider social impact, healthcare resource use and costs): patient burden survey through web platform, starting 1 August 2021 (pending ERC approval) and ending 31 December 2021. Participants have 1 week to fill out the online survey and are expected to need a total of 10 minutes for this.

Onderzoeksproduct en/of interventie

N/A

Contactpersonen

Publiek

Sobi
Sjoerd Visser-Peereboom

0653410388

Wetenschappelijk

Sobi
Sjoerd Visser-Peereboom

0653410388

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

A subject must fulfill the following criteria in order to be included in the study:
1. Men or women ≥18 years of age
2. Formal diagnosis of primary ITP according to the ASH and ICR guidelines [14, 25]
3. Currently or have previously received a TPO-RA (either eltrombopag and/or romiplostim) in the last 12 months
4. Have been treated with a TPO-RA for a minimum of 3 months, with at least some of the treatment received in the last 12 months
5. Provide written informed consent
6. Ability to understand and respond in English; this does not need to be the participants' first language or even their own language if they wish to use their own translator. If recruitment appears to be limited by this, then translations of the survey will be made. Further plans for deployment will also see the survey translated into Dutch, French, German, Italian and Spanish

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

The presence of any of the following will exclude a subject from inclusion in the study:
1. Known secondary immune thrombocytopenia

2. Foreseeable inability to cooperate with given instructions or study procedures
3. Inability to give consent

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Anders
Toewijzing:	N.v.t. / één studie arm
Blindering:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-08-2021
Aantal proefpersonen:	150
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nee

Ethische beoordeling

Positief advies

Datum:	17-06-2021
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL9571
Ander register	MEC-U : W21.145/ NWMO21.05.021

Resultaten